Australian medical technologies to scope the European market
Announcement posted by UniQuest Pty Limited 14 Nov 2011
A wearable, discreet cardiovascular vital signs monitor developed at the University of Technology, Sydney (UTS) and a portable device for diagnosing the severity of whiplash from The University of Queensland (UQ) are among more than 25 cutting edge medical innovations that leading university research commercialisation company UniQuest will be promoting at the 2011 Medica conference, Europe’s largest medical technology industry meeting.
Held in Dusseldorf, Germany, from 16 – 19 November, this year’s event is expected to attract nearly 140,000 participants.
Other new technologies featured in UniQuest’s ‘medtech’ portfolio include drug delivery and formulation mechanisms; monitoring, diagnostics and screening systems; clinical practice management and training tools; and Allied Health and assistive technologies to help patients recover from stroke, injury and the side effects of disease treatments (full list available on https://www.uniquest.com.au/medical-devices).
“Medica is the world’s largest medical innovation trade fair, so it’s the ideal place for showcasing technologies emerging from Australian university research that are addressing global health issues, such as access, aging populations and preventable diseases,” said UniQuest Managing Director, David Henderson.
“With about half the delegates from European Union countries and the remainder from Asia, the Americas and Africa, Medica presents a valuable opportunity for UniQuest to talk to major international companies about the competitive edge to be gained from licensing our technologies, and about collaborating with Australian researchers to improve health outcomes around the world.
“Medica also attracts investors looking to be involved with the next blockbuster medical innovation, and the comparative strength of the national economy has positioned Australia within their sights. UniQuest-licensed innovations, for example, are now generating annual sales of more than A$3 billion globally, from vaccines like Gardasil to high-tech MRI machines and telehealth systems, so there’s a lot of interest in what the research institutions we represent are working on right now to benefit future generations.”
UniQuest’s medical technology portfolio includes innovations from its commercialisation partners: The University of Queensland, University of Technology, Sydney, University of Wollongong, Mater Medical Research Institute, James Cook University, University of Tasmania, and Queensland Health.
UniQuest’s projects are among the 1000+ Australian biotechnology and medical technology enterprises contributing to the industry’s global growth. Of the 151 healthcare and biotech companies listed on the Australian Securities Exchange, 27 were capitalised at greater than A$100 million this year.